You may be correct. At least they make money whereas many of the cyber security stocks don't. Anyway, I'll stay for awhile and see what happens. Thanks
Why do analyst downgrade or upgrade any particular stock? They are not just good neighbors they have selfish motives for sure. They want to make money and they want you to make it for them. Credit Suisse does make good chocolate and cheese. I'll give them credit for that.
Just completed 8 weeks of Harvoni. Virus not detectable at this point in time. Zero side effects. One pill per day. Some promising drugs in pipeline. New push into fatty liver disease (much larger market than Hep). Leader in HIV. Leader in Hep C. Money running out their ying yang. Guidance less than exaggerated expectations of the "street". Stock down by $5. Does it make sense. Of course not. This is market that punishes many good companies and rewards some real dogs. I'm not a day trader and have no intention of selling. If it goes down into the low to mid $90, I will buy more. Traders after hours are of no interest to me.
Initially up $2+ after beating estimates and declaring 43 cent dividend. Then down $5 because they said they would continue to do what they have been doing. I'm simply not smart enough to understand why. Gilead is not a one trick pony but apparently the "street" thinks it is. I own CELG too and they have taken a hit after posting very good quarterly results. I think perhaps I should sell these two stellar stocks and buy some dog that loses mucho money and provides nothing of benefit to humanity. Maybe it would go up.
I have three doses of Harvoni remaining on a 8 weeks treatment regime. After week 6 I had NO detectable virus. Had absolutely NO side effects. Gilead's Harvoni is FAR superior to Abbvie's considering the dosage required and the need to use Ribavirin in some cases. Harvoni is ONE pill per day! No side effects of any consequence other than maybe headaches experienced by some. I had ZERO side effects. Now that Gilead has lowered their price to be competitive with Abbvie and can not understand why any doctor would prescribe any treatment other than Harvoni.
You're really nothing but a mean-spirited fool and most recognize that. No one will listen to your ramblings because they are not based in science and/or finance. You have my pity and I wish you a good day.
The Trout Group does in fact represent many companies in the Life Science's arena. If those that have called you a liar had done their research they would know that. In fact, if you go to The Trout Group's homepage you will see a picture of Tricia Trueheart and a list of all the companies The Trout Group represents, including Achillion.
I find it amusing that Cramer is now saying how the Abbvie/Express Script deal has apparently not presented a new paradigm is drug pricing. He should read what his minions write. Adam Feurstein said exactly the opposite only a few short days ago and Cramer, at that time, agreed with him. I would take what Adam writes with a grain of salt. His claim to fame as a biotech expert comes from the reality that he was a realtor in San Francisco. He is often wrong but even a stopped clock is right twice a day.
I understand why insiders often sell shares. They may want to diversify their investments, build a new home, or send their kid to Harvard. Sometimes they sell their company shares because they know there are problems ahead. But I can only think of one reason insiders would buy shares in their company. They must believe that their company is undervalued for some reason or another. It seems to me the faith insiders show in SGEN by buying so many shares is bullish. Perhaps there is a reason I haven't considered and would appreciate any illumination.
It's always about the money. Express Scripts is about the money. Gilead is about the money. It's always about the money. Having wrote that, Gilead is not a one trick pony. They have some promising drugs in their oncology pipeline and they have a certificate they recently bought that gives them the right to exercise a priority review from the FDA. I would like to see Gilead buy ACHN which reported positive results on a potential 4 week treatment for HVC. Their protease inhibitor is combined with Sovaldi and showed 100% effectiveness in 6 weeks of treatment. I also think that if Gilead can afford to sell Harvoni in France for $56000 for a 12 week regimen they can afford to lower their price here in the United States. All of these companies are using the basic research conducted by our government in these protease inhibitors from many years ago. I know people vote with their pocketbooks and companies conduct business based on their pocketbooks. There needs to be a compromise.
The company wouldn't bring this talent on and the talent wouldn't come on unless they felt the technology works.
Your concern for those long Inovio is truly heartwarming. It's nice to have good people like you looking out for others.
Because they are truly concerned about the long's well being. Shorts are caring people with a positive outlook on life and hearts full of love and caring.
There are some rude and some civil on this board. I only read certain post that appear to be from individuals that have done their research. As far a those that simply post an opinion, everyone has a right to their own opinion but they don't have a right to their own facts. Of course Gilead will face competition. Of course Gilead will have failures. But Gilead is not a one trick pony. Leader in HIV. Leader in Hep C. Strong pipeline in oncology. Very, very strong balance sheet. Looks like a strong buy to me but that's just my opinion.
Sentiment: Strong Buy